Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 26;13(1):e0190989.
doi: 10.1371/journal.pone.0190989. eCollection 2018.

IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals

Fekadu Abebe  1 , Mulugeta Belay  2 , Mengistu Legesse  3 , Franken K L M C  4 , Tom H M Ottenhoff  4
Affiliations

IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals

Fekadu Abebe et al. PLoS One. .

Abstract

As part of a major project to investigate protective and diagnostic immune markers against tuberculosis (TB), we measured antibody isotype responses to Mycobacterium tuberculosis (Mtb) antigens (LAM, Rv2031, and HBHA) in cohorts of 149 pulmonary tuberculosis patients (PTBP), 148 household contacts (HHCs), and 68 community controls (CCs) in an endemic setting. ELISA was used to measure levels of IgA, IgG, and IgM from sera of cohorts at baseline, and at 6 and 12 months from entry. The results show that there were significant differences in IgA, IgG, and IgM responses to the different antigens and in the three cohorts. At baseline, the level of IgM against RV2031 and LAM did not vary between cohorts, but the levels of IgA and IgG against Rv2031 were significantly higher in PTB patients than HHCs and CCs, followed by HHCs, and the lowest in CCs. In patients, there was a significant variation in antibody responses before and after chemotherapy. The levels of IgA and IgG against HBHA, and IgA against Rv2031 decreased significantly and remained low, while IgA and IgG against LAM increased significantly and remained high following chemotherapy. However, the levels of IgM against Rv2031 and LAM increased at 6 months but decreased again at 12 months. IgM against HBHA did not show any significant variation before and after chemotherapy. Similarly, there were also significant variations in antibody responses in HHCs over time. Our results show that there are significant variations in IgA, IgG and IgM responses to the different antigens and in the three cohorts, implying that not all antibody isotype responses are markers of clinical TB. In addition, the current and previous studies consistently show that IgA and IgG against Rv2031 discriminate between clinical disease, Mtb-infected and non-infected individuals.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
(a-c). IgG responses to LAM at baseline in the three cohorts (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. *p<0.05; ****p<0.0001.
Fig 2
Fig 2
(a-c). IgA responses to LAM at baseline in the three cohorts (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. **p<01*p; ***p<0.001; ****p<0.0001.
Fig 3
Fig 3
(a-c). IgM responses to LAM at baseline in the three cohorts (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. ***p<0.001; ****p<0.0001.
Fig 4
Fig 4
(a-c). IgG responses Rv2031 at baseline (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively.*p0.05; **p<0.01; ***p<0.001; ****p<0.0001.
Fig 5
Fig 5
(a-c). IgA responses to Rv2031 at baseline (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. *p<0.05; ****p<0.0001.
Fig 6
Fig 6
(a-c). IgM responses to Rv2031 at baseline (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. ****p<0.0001.
Fig 7
Fig 7
(a-c). IgG responses to HBHA at baseline (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. ****p<0.0001.
Fig 8
Fig 8
(a-c). IgM responses to HBHA at baseline (Fig a), 6 and 12 months in patients (Fig b) and HHCs (Fig c). Results are individual responses expressed as OD values. The median for each group is shown as horizontal bar. Kruskal-Wallis and Friedman test with Dunn`s multiple comparisons were used to compare antibody responses among groups and over time, respectively. ****p<0.0001.
See this image and copyright information in PMC

References

    1. WHO. Global Tuberculosis Report 2016. WHO, Geneva; 2016
    1. Kaufmann SHE, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect dis 2017; 56: 263–267. doi: 10.1016/j.ijid.2016.10.018 - DOI - PubMed
    1. Kaufmann SHE, Fortune S, Pepponi H, Ruwald M, Schrager LK, Ottenhoff TMH. TB biomarkers, TB correlates and human challenge models: New tools for improving assessment of new TB vaccines. Tuberculosis 2016; 99: S8–S11. doi: 10.1016/j.tube.2016.05.010 - DOI - PubMed
    1. Chegou NN, Essone PN, Loxton AG, Stanley K, Black GF, van der Spuy GD et al. potential of host markers produced by infection phase-dependent antigen-stimulated cells for diagnosis of tuberculosis in a highly endemic area. Plos One 2012;7(8). doi: 10.1371/journal.pone.0038501 - DOI - PMC - PubMed
    1. Abebe F. Is interferon-gamma the right marker for bacilli-Calmette-Guerin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin Exp Immunol 2012; 169 (3):213–219. doi: 10.1111/j.1365-2249.2012.04614.x - DOI - PMC - PubMed

Publication types

MeSH terms